Prot #D081DC00007: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment w

Project: Research project

Project Details

Effective start/end date4/7/174/7/20


  • Covance Inc. (Prot #D081DC00007 // Prot #D081DC00007)
  • AstraZeneca Pharmaceuticals LP (Prot #D081DC00007 // Prot #D081DC00007)